New Two-Pronged attack on debilitating Crohn's disease
NCT ID NCT03167437
Summary
This study is testing a two-part treatment for adults with moderate-to-severe Crohn's disease that isn't controlled by standard medicines. First, researchers want to see if a drug called vorinostat is safe and can reduce gut inflammation and symptoms. If it works, participants may then receive a long-term maintenance drug, ustekinumab, for up to two years to try and keep the disease under control.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.